The oncology biosimilar market is growing rapidly as cancer prevalence rises and healthcare systems seek more cost-effective alternatives to high-cost reference biologics. The market was valued at USD 10.15 billion in 2024 and is projected to reach USD 34.82 billion by 2032, expanding at a CAGR of 16.65%. 1115

Oncology biosimilars are highly similar versions of approved biologic medicines used in cancer treatment and supportive care. They undergo regulated evaluation to demonstrate similarity in quality, safety, and clinical performance for their approved uses. Biosimilars can help increase competition, reduce treatment costs, and broaden access to important biologic therapies.

Lung cancer is the largest therapeutic-area segment in the report, projected to grow from USD 2.5 billion in 2024 to USD 8.7 billion by 2032. Breast cancer, colorectal cancer, leukemia, and Hodgkin’s lymphoma are also major areas of demand.

Monoclonal antibodies are a central biosimilar category because they are used in many cancer-care protocols. Hormonal therapies and cytokine biosimilars also contribute to market expansion. Supportive-care biosimilars, such as products used to help manage treatment-related complications, are particularly important in oncology practice.

Intravenous administration remains the leading route because many cancer biologics are delivered in hospitals and oncology clinics. Subcutaneous delivery is gaining interest because it may improve convenience for appropriate patients and reduce time spent in infusion settings.

Hospitals are the largest end-use segment due to the need for specialist oncology teams, infusion infrastructure, diagnostic support, and patient monitoring. Oncology clinics and homecare settings are expected to become increasingly relevant as treatment delivery becomes more patient-centered.

North America leads the market, supported by strong regulatory infrastructure, established cancer-care networks, and high biologic use. Europe is also significant, while Asia-Pacific is expected to grow rapidly as cancer-treatment access, biosimilar production, and healthcare investment expand.

Read more: Oncology Biosimilar Market 1115

FAQs

Q1. What is an oncology biosimilar?
It is a biologic medicine shown to be highly similar to an approved reference biologic used in cancer-related treatment or supportive care.

Q2. Why are oncology biosimilars important?
They can improve access to biologic cancer therapies by increasing competition and helping manage treatment costs.

Tags: oncology biosimilar market, cancer biosimilars, monoclonal antibodies, affordable cancer treatment, biologic therapies